IONIS PHARMACEUTICALS INC
For the period ended Mar 31, 2026. Filed Apr 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 29, 2026
IONS$28.19-9.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| Operating activities: | ||
| Net loss | $(92,528) | $(146,938) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 3,301 | 2,228 |
| Amortization of right-of-use operating lease assets | 3,485 | 2,587 |
| Amortization of other assets | 661 | 582 |
| Amortization of discount on investments, net | (6,190) | (7,108) |
| Amortization of debt issuance costs | 2,349 | 1,642 |
| Non-cash royalty revenue related to sale of royalties | (11,689) | (12,891) |
| Non-cash interest related to sale of future royalties | 17,184 | 18,670 |
| Stock-based compensation expense | 43,275 | 29,718 |
| Loss (gain) on investments, net | (22,583) | 1,849 |
| Non-cash losses related to other assets | 40 | 61 |
| Changes in operating assets and liabilities: | ||
| Escrow deposit for maturity of 0 percent convertible senior notes due April 2026 | (632,511) | - |
| Contracts receivable | (7,625) | 52,481 |
| Inventories | 338 | 1,010 |
| Other current and long-term assets | (7,390) | (12,366) |
| Accounts payable | (3,095) | (25,968) |
| Income taxes | 161 | 92 |
| Accrued compensation | (80,187) | (43,039) |
| Accrued liabilities and other liabilities | 21,003 | 333 |
| Deferred contract revenue | (20,818) | (13,718) |
| Net cash used in operating activities | (792,819) | (150,775) |
| Investing activities: | ||
| Purchases of short-term investments | (192,755) | (311,068) |
| Proceeds from sale of short-term investments | 752,824 | 494,755 |
| Purchases of property, plant and equipment | (21,763) | (12,577) |
| Acquisition of licenses and other assets, net | (1,486) | (651) |
| Net cash provided by investing activities | 536,820 | 170,459 |
| Financing activities: | ||
| Proceeds from issuance of common stock through equity plans, net | 57,302 | 2,241 |
| Principal payments on mortgage debt | (44) | (42) |
| Net cash provided by financing activities | 57,258 | 2,199 |
| Effects of exchange rates on cash | (138) | 232 |
| Net increase (decrease) in cash and cash equivalents | (198,879) | 22,115 |
| Cash and cash equivalents at beginning of period | 372,260 | 242,077 |
| Cash and cash equivalents at end of period | $173,381 | $264,192 |
| Supplemental disclosures of cash flow information: | ||
| Interest paid | $90 | $92 |
| Income tax refunds received, net | $(8) | $(400) |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Amounts accrued for capital and patent expenditures | $1,043 | $460 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.